Incomplete brain tumor removal always causes neurologic deficit, disease recurrence and high mortality. Protoporphyrin IX (PpIX) accumulated in glioma cells with exogenous 5-aminolevulinic acid (5-ALA) serves as contrast agent for fluorescence-guided surgery and as well as acts as a photosensitizer for photodynamic therapy (PDT). However, the accurate tumor delineation using PpIX is limited by autofluorescence and superficial penetration depth. LS301 is a tumor-targeted near-infrared (NIR) contrast agent developed in our lab which allows deeper tumor imaging and avoids autofluorescence. My project aims to investigate whether LS301 can improve PpIX mediated PDT and tumor removal surgery. We have demonstrated co-localization of LS301 and PpIX in DBT and U87-MG glioma cell lines and are currently testing the effect of LS301 on PpIX mediated PDT in vitro. We will also compare LS301-PpIX with PpIX only PDT and tumor removal in mouse models of brain cancer. This study can potentially increase efficacy of PDT and fluorescence-guided brain tumor resection.
","abstract_html":"<p>Incomplete brain tumor removal always causes neurologic deficit, disease recurrence and high mortality. Protoporphyrin IX (PpIX) accumulated in glioma cells with exogenous 5-aminolevulinic acid (5-ALA) serves as contrast agent for fluorescence-guided surgery and as well as acts as a photosensitizer for photodynamic therapy (PDT). However, the accurate tumor delineation using PpIX is limited by autofluorescence and superficial penetration depth. LS301 is a tumor-targeted near-infrared (NIR) contrast agent developed in our lab which allows deeper tumor imaging and avoids autofluorescence. My project aims to investigate whether LS301 can improve PpIX mediated PDT and tumor removal surgery. We have demonstrated co-localization of LS301 and PpIX in DBT and U87-MG glioma cell lines and are currently testing the effect of LS301 on PpIX mediated PDT in vitro. We will also compare LS301-PpIX with PpIX only PDT and tumor removal in mouse models of brain cancer. This study can potentially increase efficacy of PDT and fluorescence-guided brain tumor resection.</p>","abstract_has_math":false,"creators":["Zhang, Haini"],"institution":null,"degree_name":"Master of Science (MS)","degree_level":"Thesis","degree_discipline":"Biomedical Engineering","degree_department":null,"school":null,"contributors":["Samuel Achilefu","Monica Shokeen, Quing Zhu"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2017,"date_issued":"2017-12-20T08:00:00Z","date_published":"2017-12-20T08:00:00Z","updated_at":"2026-07-24T06:13:05Z","subjects":["brain cancer","Analytical, Diagnostic and Therapeutic Techniques and Equipment","Biomedical Engineering and Bioengineering","Engineering"],"languages":["English (en)"],"rights":["I have not registered my thesis with the U.S. Copyright Office, and do not intend to."],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["https://openscholarship.wustl.edu/eng_etds/271"],"render_values":[{"text":"https://openscholarship.wustl.edu/eng_etds/271","href":"https://openscholarship.wustl.edu/eng_etds/271","code":true}]}]},"links":{"outbound_url":"https://doi.org/10.7936/K7319V99","outbound_label":"DOI","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Samuel Achilefu","Monica Shokeen, Quing Zhu"]},{"key":"dc:creator","label":"Author","values":["Zhang, Haini"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2020-01-17T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biomedical Engineering","McKelvey School of Engineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["brain cancer","Analytical, Diagnostic and Therapeutic Techniques and Equipment","Biomedical Engineering and Bioengineering","Engineering"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English (en)"]},{"key":"dc:rights","label":"Dc Rights","values":["I have not registered my thesis with the U.S. Copyright Office, and do not intend to."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://doi.org/10.7936/K7319V99","https://openscholarship.wustl.edu/eng_etds/271"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Permanent URL: https://doi.org/10.7936/K7319V99"]},{"key":"dc:description.abstract","label":"Abstract","values":["Incomplete brain tumor removal always causes neurologic deficit, disease recurrence and high mortality. Protoporphyrin IX (PpIX) accumulated in glioma cells with exogenous 5-aminolevulinic acid (5-ALA) serves as contrast agent for fluorescence-guided surgery and as well as acts as a photosensitizer for photodynamic therapy (PDT). However, the accurate tumor delineation using PpIX is limited by autofluorescence and superficial penetration depth. LS301 is a tumor-targeted near-infrared (NIR) contrast agent developed in our lab which allows deeper tumor imaging and avoids autofluorescence. My project aims to investigate whether LS301 can improve PpIX mediated PDT and tumor removal surgery. We have demonstrated co-localization of LS301 and PpIX in DBT and U87-MG glioma cell lines and are currently testing the effect of LS301 on PpIX mediated PDT in vitro. We will also compare LS301-PpIX with PpIX only PDT and tumor removal in mouse models of brain cancer. This study can potentially increase efficacy of PDT and fluorescence-guided brain tumor resection.
"]},{"key":"dc:title","label":"Title","values":["LS301 Fluorescence-guided Photodynamic Therapy of brain cancer using PpIX photosensitizer"]}]}],"canonical_facts":{"dc:contributor":["Samuel Achilefu","Monica Shokeen, Quing Zhu"],"dc:creator":["Zhang, Haini"],"dc:date.available":["2020-01-17T08:00:00Z"],"dc:description":["Permanent URL: https://doi.org/10.7936/K7319V99"],"dc:description.abstract":["Incomplete brain tumor removal always causes neurologic deficit, disease recurrence and high mortality. Protoporphyrin IX (PpIX) accumulated in glioma cells with exogenous 5-aminolevulinic acid (5-ALA) serves as contrast agent for fluorescence-guided surgery and as well as acts as a photosensitizer for photodynamic therapy (PDT). However, the accurate tumor delineation using PpIX is limited by autofluorescence and superficial penetration depth. LS301 is a tumor-targeted near-infrared (NIR) contrast agent developed in our lab which allows deeper tumor imaging and avoids autofluorescence. My project aims to investigate whether LS301 can improve PpIX mediated PDT and tumor removal surgery. We have demonstrated co-localization of LS301 and PpIX in DBT and U87-MG glioma cell lines and are currently testing the effect of LS301 on PpIX mediated PDT in vitro. We will also compare LS301-PpIX with PpIX only PDT and tumor removal in mouse models of brain cancer. This study can potentially increase efficacy of PDT and fluorescence-guided brain tumor resection.
"],"dc:identifier":["https://doi.org/10.7936/K7319V99","https://openscholarship.wustl.edu/eng_etds/271"],"dc:language":["English (en)"],"dc:rights":["I have not registered my thesis with the U.S. Copyright Office, and do not intend to."],"dc:subject":["brain cancer","Analytical, Diagnostic and Therapeutic Techniques and Equipment","Biomedical Engineering and Bioengineering","Engineering"],"dc:title":["LS301 Fluorescence-guided Photodynamic Therapy of brain cancer using PpIX photosensitizer"],"thesis:degree_discipline":["Biomedical Engineering","McKelvey School of Engineering"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Master of Science (MS)"]},"updated_at":"2026-07-24T06:13:05Z"}